Organon & Co. (NYSE:OGN) Declares $0.28 Quarterly Dividend

Organon & Co. (NYSE:OGN) declared a quarterly dividend on Thursday, May 2nd, Zacks reports. Investors of record on Monday, May 13th will be given a dividend of 0.28 per share on Thursday, June 13th. This represents a $1.12 annualized dividend and a yield of 5.50%. The ex-dividend date is Friday, May 10th.

Organon & Co. Price Performance

Shares of OGN stock opened at $20.37 on Thursday. The stock has a market capitalization of $5.24 billion, a price-to-earnings ratio of 4.98, a PEG ratio of 0.88 and a beta of 0.81. The company’s fifty day simple moving average is $18.35 and its two-hundred day simple moving average is $15.86. Organon & Co. has a 1 year low of $10.84 and a 1 year high of $24.08.

Organon & Co. (NYSE:OGN) last released its quarterly earnings data on Thursday, February 15th. The company reported $0.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.73 by $0.14. The company had revenue of $1.60 billion for the quarter, compared to analyst estimates of $1.55 billion. Organon & Co. had a negative return on equity of 259.73% and a net margin of 16.50%. Equities research analysts anticipate that Organon & Co. will post 4.1 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. Piper Sandler boosted their price objective on shares of Organon & Co. from $22.00 to $24.00 and gave the company an “overweight” rating in a research note on Monday, April 29th. The Goldman Sachs Group upped their price target on shares of Organon & Co. from $18.00 to $20.00 and gave the stock a “neutral” rating in a report on Friday, May 3rd.

Insider Transactions at Organon & Co.

In related news, insider Kirke Weaver bought 2,720 shares of the business’s stock in a transaction that occurred on Thursday, February 22nd. The stock was bought at an average cost of $18.36 per share, for a total transaction of $49,939.20. Following the completion of the transaction, the insider now owns 15,181 shares of the company’s stock, valued at $278,723.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 1.17% of the company’s stock.

About Organon & Co.

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.